ライフサイエンスコーパス: bone marrow transplant

1 and Functional Assessment of Cancer Therapy-Bone Marrow Transplant.

2 in the peripheral blood of NHP recipients of bone marrow transplant.

3 mphoid organs of recipients of an allogeneic bone marrow transplant.

4 al treatments, such as radiation therapy and bone marrow transplant.

5 perimental parent C57BL/6-->CB6F1 allogeneic bone marrow transplant.

6 obilization in preparation for an autologous bone marrow transplant.

7 ng repopulation of the immune system without bone marrow transplant.

8 (CML) after treatment with IFN or allogeneic bone marrow transplant.

9 injury after myeloablative chemotherapy and bone marrow transplant.

10 s hematopoietic recovery in mice receiving a bone marrow transplant.

11 mprove the homing of HSC after an autologous bone marrow transplant.

12 pthatic pneumonia syndrome (IPS) following a bone marrow transplant.

13 41 years in patients who had not received a bone marrow transplant.

14 but were normalized in mice that received a bone marrow transplant.

15 rotein, used as an immunostimulant following bone-marrow transplant.

16 d is predicated on >40 years of success with bone marrow transplants.

17 mismatched) or female (sex-matched, control) bone marrow transplants.

18 patients with hematological malignancies and bone marrow transplants.

19 or allogeneic and identical twin (syngeneic) bone marrow transplants.

20 rmed in Bambi(+/+) mice receiving Bambi(-/-) bone marrow transplants.

21 aematopoietic cells following congenic mouse bone marrow transplants.

22 e cortex were found in HD mice that received bone marrow transplants.

23 TBI and were able to prevent engraftment of bone marrow transplants.

24 t clinical data from 21 patients following a bone marrow transplant, 13 of which progress to idiopath

25 In comparison with allele-matched bone-marrow transplants, 5-year leukaemia-free survival

26 do not develop efficiently in the thymus of bone marrow transplanted adult tgepsilon26 mice, which h

27 lovirus (CMV) infection following allogeneic bone marrow transplant (allo-BMT) is controlled by donor

28 t-chain fatty acids (SCFAs) after allogeneic bone marrow transplant (allo-BMT).

29 ibute to activation of APCs after allogeneic bone marrow transplant (alloBMT), we examined whether th

30 o syngeneic wild-type mice via Tgfbr2(Myeko) bone marrow transplant and can be rescued in Tgfbr2(Myek

31 rts of 121 pediatric patients who received a bone marrow transplant and subsequently required mechani

32 nfarct fibroblasts using lineage tracing and bone marrow transplants and a robust marker for cardiac

33 ss has led to effective therapies, including bone marrow transplants and gene therapy, that would hav

34 m the lungs and by rejection of incompatible bone marrow transplants and in vitro by cytolysis of YAC

35 Secondary bone marrow transplants and integration site analysis co

36 y observed in recipients of solid organs and bone marrow transplants and is associated with increased

37 hat CHQ may impair rejection of incompatible bone marrow transplants and other functions mediated by

38 Patients who received mismatched bone marrow transplants and those who received mismatche

39 pe bone marrow-transplanted mice, ROCK2(+/-) bone marrow-transplanted and ROCK2(-/-) bone marrow-tran

40 marrow and its differentiated progeny after bone marrow transplant, and several mouse hematopoietic

41 fection, leukemia, lymphoma, solid organ and bone marrow transplants, and inherited immune deficienci

42 application of hematopoietic stem cells for bone-marrow transplant, and further elucidation of homin

43 y detected by histology in tumors taken from bone marrow transplanted animals, they were spatially is

44 In this study, a bone marrow transplant approach was used to investigate

45 acute phase response proteins at the time of bone marrow transplant are highly likely to develop IPS

46 Bone marrow transplants are an important therapeutic too

47 b; 1 died 6 months after a matched unrelated bone marrow transplant as a result of undefined encephal

48 a complete remission received an allogeneic bone marrow transplant as consolidation.

49 Furthermore, in a murine bone marrow transplant assay, genetic deficiency in RSK2

50 Bone marrow transplant assays and examination of steady-

51 C numbers and premature exhaustion in serial bone marrow transplant assays.

52 toGvHD occurs spontaneously after autologous bone marrow transplant (autoBMT) in the absence of CsA i

53 Finally, the results of reciprocal bone marrow transplants between Cx43+/+ and Cx43+/- mice

54 ociated multifactorial disease of allogeneic bone marrow transplant (BMT) -induced graft-vs.-host dis

55 logenous leukemia (AML) and those undergoing bone marrow transplant (BMT) are at greatest risk for co

56 Here, we used a murine bone marrow transplant (BMT) assay to test the transform

57 locus were nonrandomly assigned to receive a bone marrow transplant (BMT) by using oral busulfan (16

58 FNgamma and IL-6 polymorphisms in 80 sibling bone marrow transplant (BMT) donor/recipient pairs.

59 ntinued over several months before and after bone marrow transplant (BMT) from his RSV-immune father.

60 ion-negative patients received an allogeneic bone marrow transplant (BMT) in first complete remission

61 We used a murine syngeneic bone marrow transplant (BMT) model, in which administrat

62 fatal myeloproliferative disease in a murine bone marrow transplant (BMT) model, whereas T/T(F) cause

63 ematopoietic and lymphoid cells in the mouse bone marrow transplant (BMT) model.

64 NF-alpha receptors as donors in well-defined bone marrow transplant (BMT) models.

65 ase (aGVHD) in 2 different murine allogeneic bone marrow transplant (BMT) models.

66 Using our syngeneic bone marrow transplant (BMT) mouse model, BMT mice with

67 We previously reported that murine bone marrow transplant (BMT) neutrophils overexpress cyc

68 yelogenous leukemia (CML), either allogeneic bone marrow transplant (BMT) or interferon-alpha2b (IFN-

69 all the hematopoietic tissues of 16 primary bone marrow transplant (BMT) recipient mice and 14 secon

70 L challenge in both syngeneic and allogeneic bone marrow transplant (BMT) recipients at both early an

71 driven responses, was that rearrangements in bone marrow transplant (BMT) recipients exhibited much l

72 V), causing fatal disseminated infections in bone marrow transplant (BMT) recipients, are associated

73 ociated T-cell deficiency seen in allogeneic bone marrow transplant (BMT) recipients.

74 However, there are unusually high bone marrow transplant (BMT) rejection rates in these pa

75 graft tolerance in mice receiving allogeneic bone marrow transplant (BMT) with minimal conditioning.

76 ed States; yet, the only curative therapy, a bone marrow transplant (BMT), is seldom applied.

77 f CYA to recipient mice for 12 days prior to bone marrow transplant (BMT), of glucocorticosteroids on

78 We found that cerebral engraftment by bone marrow transplant (BMT)-derived wild-type or EP2(-/

79 CML at various time points after allogeneic bone marrow transplant (BMT).

80 of systemic lupus erythematosus, were given bone marrow transplants (BMT) at 20 wk of age using MHC-

81 Using cross bone marrow transplants (BMT) between young and old fema

82 We performed bone marrow transplants (BMT) from green fluorescent pro

83 trated that SHIP(-/-) mice accept allogeneic bone marrow transplants (BMT) without significant acute

84 Bone marrow-transplanted (BMT) XSCID dogs not only engra

85 One-half of bone-marrow transplant (BMT) and stem-cell transplant re

86 A baboon bone-marrow transplant (BMT) was performed in an attempt

87 ukemia (CML) underwent unrelated donor (URD) bone marrow transplants (BMTs) facilitated by the Nation

88 consolidation chemotherapy and an autologous bone marrow transplant, but eventually died 22 months af

89 KGF-/- recipients of syngeneic or allogeneic bone marrow transplant, but using KGF-/- mice as a donor

90 ells (HSCs) are the therapeutic component of bone marrow transplants, but finding immune-compatible d

91 Intestinal IL-22 was produced after bone marrow transplant by IL-23-responsive innate lympho

92 tment of tumor-bearing Tg/NCD mice or Tg/NCD bone marrow transplanted C3H mice (Tg/NCD-C3H) resulted

93 cts that can be corrected with an allogeneic bone marrow transplant can theoretically also be treated

94 ther specific subsets of cells in allogeneic bone marrow transplants can effectively treat the BCL(1)

95 xty-three percent of 24 NCs collected from a bone marrow transplant center contained biofilms compris

96 signaling in PcP-related lung injury, murine bone marrow transplant chimeras of wild-type, C57BL6/J,

97 We exposed bone marrow transplant chimeric mice to hypoxia and trea

98 Using gfp(+) bone marrow-transplant chimeric mice, we demonstrate tha

99 s assessed with European Group for Blood and Bone Marrow Transplant criteria.

100 Secondary bone marrow transplants demonstrated continued equivalen

101 the adult brain 1 to 6 months after an adult bone marrow transplant demonstrates a remarkable plastic

102 d that myeloablative irradiation followed by bone marrow transplant-derived microglia engraftment, ra

103 Ldlr(-/-) mice with a Nur77(-/-)-deficient bone marrow transplant developed 2.1-fold larger atheros

104 ients who responded to therapy who underwent bone marrow transplant did not show any benefit from thi

105 Unfortunately, unless combined with a bone marrow transplant, disease relapse is frequent.

106 suggested, and indicate that improvement of bone marrow transplant efficiency may be possible in the

107 diated in vivo LTbetaR stimulation following bone marrow transplant enhances initial thymus recovery

108 In a green fluorescent protein bone marrow transplant experiment we found green fluores

109 However, bone marrow transplant experiments and cell type-specifi

110 Murine bone marrow transplant experiments demonstrate that JAK2

111 Mechanistically, bone marrow transplant experiments demonstrate that TBI

112 Reciprocal bone marrow transplant experiments identified that loss

113 We conducted bone marrow transplant experiments in which we transferr

114 Bone marrow transplant experiments revealed that leukocy

115 not affect leukocyte functions in vitro, and bone marrow transplant experiments suggest that host Akt

116 HSCs fail to compete with wild-type HSCs in bone marrow transplant experiments.

117 Bone marrow-transplant experiments using IFN-gammaR-/- m

118 the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) were received from 109

119 in individuals who had previously received a bone marrow transplant for hematological disorders.

120 s erythematosus, and conditioning regimen of bone marrow transplant for Hurler's syndrome.

121 accinia virus, followed by combined skin and bone marrow transplant from a BALB/c donor.

122 osis and (2) a female patient who received a bone marrow transplant from a male donor and subsequentl

123 In the female recipient of a bone marrow transplant from a male donor, 12.4% of the m

124 adequate immune reconstitution despite prior bone marrow transplant from a parent.

125 Allogeneic bone marrow transplant from an HLA-matched sibling can h

126 d in nontransgenic SCID mice that received a bone marrow transplant from GFP-expressing SCID mice.

127 Rats status post 5/6 nephrectomy underwent bone marrow transplant from human placental alkaline pho

128 An HLA-identical bone marrow transplant from the mother led patient 1 to

129 1(-/-) rats was almost completely rescued by bone marrow transplanted from FHH controls.

130 Bone marrow transplants from Arg2-deficient mice did not

131 Control mice that received bone marrow transplants from control mice had an influx

132 inflammation and liver damage in mice given bone marrow transplants from Cyp27a1(-/-) mice and place

133 In Ldlr(-/-) mice that received bone marrow transplants from Cyp27a1(-/-) mice, lysosome

134 ion was inhibited, irradiated mice receiving bone marrow transplants from heterozygous GFP+ mice reve

135 H pylori-infected control mice that received bone marrow transplants from LysMCre/Smo(KO) mice.

136 brain samples from females who had received bone marrow transplants from male donors.

137 ported by experiments in which recipients of bone marrow transplants from SR-uPA+/0 donors but not no

138 onto Fgfbp1 GFP-knock-in reporter hosts and bone marrow transplants from the GFP-reporter model into

139 FVIII(null) mice that received bone marrow transplants from wild-type donors were still

140 ite numerous reports of GBS in recipients of bone marrow transplants, GBS has rarely been reported in

141 ." Ablation of the immune system followed by bone marrow transplant has been shown to cure experiment

142 re, predictors for 5-year mortality included bone marrow transplant (hazard ratio, 3.66; 95% CI, 2.26

143 reover, generating chimeric mice via UPRT(+) bone marrow transplants identifies immune versus niche s

144 u/CY conditioning, for HLA-identical sibling bone marrow transplants in children with ALL.

145 Based on reciprocal bone marrow transplants in conjunction with assessment o

146 have been utilized extensively in allogeneic bone marrow transplants in order to purge the allograft

147 ould potentially overcome the limitations of bone marrow transplants, including graft rejection and t

148 late toxicities in some children who receive bone marrow transplants, including impaired growth and i

149 years after the first successful allogeneic bone marrow transplants, infection remains the most comm

150 was achieved using CD11c-Cre x Tcf4(-/flox) bone marrow transplanted into Ldlr(-/-) mice.

151 We report here that following syngeneic bone marrow transplants into lethally irradiated C57BL6

152 We conclude that immune tolerance to bone marrow transplants involves clonal deletion, and to

153 experiments involving H. felis infection of bone marrow transplanted irradiated mice have suggested

154 suggest that one mechanism for relapse after bone marrow transplant is acquired tolerance of allogene

155 opoietic stem cell transplantation (HSCT, or bone marrow transplant), is common even after transplant

156 An isolated vascularized bone marrow transplant (iVBMT) model was developed to st

157 An isolated vascularized bone marrow transplant (iVBMT) model was previously deve

158 In bone marrow-transplanted K19-kras mice that progressed t

159 s transformation in Ba/F3 cells and a murine bone marrow transplant leukemia model.

160 show that in both the steady-state and after bone marrow transplant, lymphotoxin beta receptor (LTbet

161 LTbeta-null mice that received WT bone marrow transplants maintained mutant hair phenotype

162 T cells present in an allogeneic bone marrow transplant may produce graft-versus-host dis

163 flammation in patients undergoing autologous bone marrow transplant may reduce the subsequent develop

164 res: Functional Assessment of Cancer Therapy-Bone Marrow Transplant, Mental Health Inventory, occupat

165 In the bone marrow transplant mice, double immunofluorescent st

166 cent studies have shown that in radiated and bone marrow transplanted mice, bone marrow-derived cells

167 of a polymeric IL-8 delivery system into GFP bone marrow-transplanted mice revealed that localized IL

168 +/-) bone marrow-transplanted and ROCK2(-/-) bone marrow-transplanted mice showed substantially less

169 Compared with wild-type bone marrow-transplanted mice, ROCK2(+/-) bone marrow-tr

170 arger atherosclerotic lesions than wild-type bone marrow-transplanted mice.

171 -expressing Tregs over time in an allogeneic bone marrow transplant model and demonstrated colocaliza

172 major histocompatibility complex-mismatched bone marrow transplant model in which graft-versus-host

173 We established a murine bone marrow transplant model of the inv(16) in which wil

174 Employing a bone marrow transplant model to compartmentalize TLR4 si

175 Further, we used a bone marrow transplant model to determine the influence

176 In this study, we used the mouse bone marrow transplant model to further explore the role

177 uce a myeloproliferative disease in a murine bone marrow transplant model, but are not sufficient to

178 Using a bone marrow transplant model, we also demonstrated that

179 Using a syngeneic murine bone marrow transplant model, we demonstrate that vaccin

180 Using a bone marrow transplant model, we previously showed that

181 ferase-expressing CIK cells in an allogeneic bone marrow transplant model.

182 les that cause aggressive T-ALLs in a murine bone marrow transplant model.

183 w chimerism can be produced in a mouse-->rat bone marrow transplant model.

184 reat ALL-bearing mice using a minor mismatch bone marrow transplant model.

185 gnificant prolongation of survival in murine bone marrow transplant models of FGFR3 TDII-induced pre-

186 hough cytokine levels are elevated in murine bone marrow transplant models of leukemia using tyrosine

187 In murine bone marrow transplant models, PD-L1 expression on host

188 y and generates a PV-like phenotype in mouse bone marrow transplant models.

189 duce a myeloproliferative syndrome in murine bone marrow transplant models.

190 ) or respiratory (odds ratio, 1.56) reasons, bone marrow transplant (odds ratio, 1.53), previous ICU

191 at GHS promoted better thymic engraftment in bone marrow transplant of SCID mice.

192 ctivation gene-deficient (Rag(-/-)) mice and bone marrow transplant of tgepsilon26 animals.

193 or alpha(V)beta(3), we performed reciprocal bone marrow transplants on wild-type and beta3(-/-) mice

194 replacement therapy, or more effectively by bone marrow transplant or HSC gene therapy (HSC-GT).

195 from five females who had received either a bone-marrow transplant or an allogeneic mobilised periph

196 status (P =.04), and early disease status at bone marrow transplant (P =.05) were associated with sup

197 CMV and human herpesvirus type 6 (HHV-6) in bone marrow transplant patients (causing marrow suppress

198 that it is possible to estimate dd-cfDNA in bone marrow transplant patients that are unrelated or th

199 ppressive agent presently being evaluated in bone marrow transplant patients to treat graft-versus-ho

200 Only among bone marrow transplant patients were overall survival (O

201 report GBS in organ transplant patients and bone marrow transplant patients, both of whom have iatro

202 ective in certain high-risk patients such as bone marrow transplant patients, few studies have focuse

203 nocompromised individuals, such as organ and bone marrow transplant patients.

204 ents and $83 to $112 per 50 mg in allogeneic bone marrow transplant patients.

205 ated with severe human disease in kidney and bone marrow transplant patients.

206 lyomavirus (BKPyV) affects mostly kidney and bone marrow transplant patients.

207 the severity of graft-versus-host disease in bone marrow transplant patients.

208 wo novel GII.4 variants in immunocompromised bone marrow transplant patients.

209 provide a functional cure, as observed in a bone marrow transplant performed with hematopoietic stem

210 Bone marrow transplants performed on wild-type and KSR1(

211 t of lung injury in the early periautologous bone marrow transplant period.

212 Bone marrow transplants point to altered stellate cell f

213 Hex bone marrow transplant recipient mice also develop hemat

214 isolated from brain abscess material from a bone marrow transplant recipient.

215 her had leukemia (n = 14) or were allogeneic bone marrow transplant recipients (n = 13).

216 encephalitis reported in the literature (13 bone marrow transplant recipients and 1 liver transplant

217 emia after months of apparent cure in recent bone marrow transplant recipients and an immediately-tre

218 in immunocompromised individuals, including bone marrow transplant recipients and cancer and AIDS pa

219 Bone marrow transplant recipients and single-ventricle p

220 TLs for adoptive immunotherapy of HLA-A*0201 bone marrow transplant recipients from 200 mL donor bloo

221 pecific DNA in the peripheral blood of islet/bone marrow transplant recipients of same sex cynomolgus

222 phomas is seen in solid organ transplant and bone marrow transplant recipients receiving immunosuppre

223 number of features that distinguish them as bone marrow transplant recipients that must be understoo

224 hybridization analysis of blood samples from bone marrow transplant recipients who had received gende

225 From an initial cohort of 12 bone marrow transplant recipients who received marrow fr

226 prognosis generally is poor among pediatric bone marrow transplant recipients who subsequently requi

227 Bone marrow transplant recipients with a documented pulm

228 During CMV reactivation in bone marrow transplant recipients, KIR(+)CD56(+) T cells

229 ncluding patients with AIDS, solid organ and bone marrow transplant recipients, patients with leukemi

230 mmunodeficiency virus-positive patients, and bone marrow transplant recipients, were tested for cytom

231 ding of the impact of respiratory viruses on bone marrow transplant recipients.

232 potential clinical uses of FTY in allogeneic bone marrow transplant recipients.

233 e a partially penetrant, long-latency AML in bone marrow transplant recipients.

234 (PBLs), and whole blood (WB) from allogeneic bone marrow transplant recipients.

235 ansplant patients or hemorrhagic cystitis in bone marrow transplant recipients.

236 nomenon is also frequently observed in human bone marrow transplant recipients.

237 suppressed individuals, including kidney and bone marrow transplant recipients.

238 Bone marrow transplants reconstituted mice with T cells,

239 Following bone marrow transplant, recovery of a normal peripheral

240 The databases of the International Bone Marrow Transplant Registry (IBMTR) and the European

241 9 to 1998 and were reported to International Bone Marrow Transplant Registry (IBMTR) or Autologous Bl

242 white patients reported in the International Bone Marrow Transplant Registry (IBMTR), 30% of 341 MDS

243 ant recipients reported to the International Bone Marrow Transplant Registry (IBMTR).

244 chronic phase provided by the International Bone Marrow Transplant Registry and the National Marrow

245 1968 to 1996, reported to the International Bone Marrow Transplant Registry and/or National Marrow D

246 for leukemia, reported to the International Bone Marrow Transplant Registry between 1985 and 1994, u

247 r results were reported to the International Bone Marrow Transplant Registry by 144 participating ins

248 published data beyond that from the European Bone Marrow Transplant Registry exist.

249 ed with those from 509 similar International Bone Marrow Transplant Registry patients who underwent t

250 5 and 1999 and reported to the International Bone Marrow Transplant Registry were included.

251 From a large European bone marrow transplant registry, a birds' eye view of st

252 one of 82 centers reporting to the European Bone Marrow Transplant Registry.

253 1989 to 1997, reported to the International Bone Marrow Transplant Registry.

254 3 centers participating in the International Bone Marrow Transplant Registry.

255 62) were recruited through the International Bone Marrow Transplant Registry/Autologous Blood and Mar

256 mune and neurodegenerative states, organ and bone marrow transplant rejection, and tumor response to

257 ed with 151 matched Center for International Bone Marrow Transplant Research controls.

258 develop myeloid and lymphoid cells received bone marrow transplants resulting in donor-derived micro

259 Subsequent bone marrow transplants revealed the contribution of bot

260 the Functional Assessment of Cancer Therapy-Bone Marrow Transplant Scale (FACT-BMT) questionnaire, w

261 observations, we found that both genetic and bone marrow-transplanted SCD mice had greater mortality

262 and safe method for immunosuppression in the bone marrow transplant setting.

263 lograft rejection in MHC-identical solid and bone marrow transplant settings.

264 Bone marrow transplant studies and quantitation of macro

265 Bone marrow transplant studies point to altered macropha

266 Furthermore, bone marrow transplant studies reveal that these improve

267 n unexpected finding was noted in allogeneic bone marrow transplant studies using IL-7 receptor null

268 Here we use sex-mismatched bone marrow transplant subjects to show that smooth musc

269 vestigations of animals and short-term human bone marrow transplants suggest that bone marrow can rep

270 Bone marrow transplants suggest that the absence of beta

271 ased bone mass could partially be rescued by bone marrow transplants supporting our hypothesis that r

272 survivors and siblings participating in the Bone Marrow Transplant Survivor Study (BMTSS) completed

273 Using resources offered by the Bone Marrow Transplant Survivor Study (BMTSS), we evalua

274 Reciprocal bone marrow transplants that involved both wild-type and

275 Bone marrow-transplanted TLR2 chimeric mice were generat

276 In addition, chimeric mice were generated by bone marrow transplant to limit expression of IL7Ralpha

277 Here, we use bone marrow transplants to generate mice chimeras that e

278 Here, we compare CD13 wild-type and null bone marrow-transplanted tumor-bearing mice to show that

279 units supplying cooled bottled water to the bone marrow transplant unit.

280 a contaminated drinking water dispenser in a bone marrow transplant unit.

281 semiallogeneic T cells, long-term after the bone marrow transplant using G-Neutrophils, were confirm

282 and cancer cells in leukemia patients after bone marrow transplants, using a system of six delay dif

283 METHODS AND Using genetic lineage tracing or bone marrow transplant, we found no evidence for collage

284 virus cases occurring in children undergoing bone marrow transplant, we undertook norovirus genome se

285 By using bone marrow transplants, we showed that MRP14 deficiency

286 g System score, and presence or absence of a bone marrow transplant were found between groups.

287 Patients with hematologic malignancy or bone marrow transplant were more likely to develop a com

288 A total of 960 recipients of solid organ or bone marrow transplants were identified from Veterans He

289 Allogeneic bone marrow transplants were performed between B6 (H2(b)

290 Reciprocal bone marrow transplants were performed to test the impor

291 had received chemotherapy, radiation, and a bone marrow transplant, were analyzed.

292 traperitoneally thioglycollate in Abcg1(-/-) bone marrow-transplanted, Western diet-fed, Ldlr-deficie

293 Treatment is bone marrow transplant, which is effective in treating t

294 from stem cells residing in the bone marrow, bone marrow transplanted wild-type mice were treated wit

295 d human leukocyte antigen-matched kidney and bone marrow transplant with lead follow-up time of more

296 However, bone marrow transplants with mature donor T cells can in

297 is during zymosan-induced peritonitis, using bone marrow transplants with transgenic mice deficient i

298 We performed bone marrow transplants with wild-type CD45.1 and CD45.2

299 low-density lipoprotein receptor (LDLR) were bone-marrow transplanted with NLRP3-deficient, ASC (also

300 ontaminating cancerous cells from autologous bone marrow transplants without perturbing the engraftme